Genmab — November 2015
-
Vi starter Q&A om 5 min.
-
Den gode hr. larsens engelsk gør altid en i godt humør
-
Dejligt at jan destruerer Elotuzumab
-
Would it be possible to make a CS1/CD38 duobody antibody? Getting the best from both Elotuzumab and daratumumab into one product to treat MM ?
11/11 15:20 af Jan Van de Winkel
In theory that is possible, but we believe we have smarter combinations in the making. -
Pressemeddelelse
København, Danmark, 11. november 2015 — Genmab A/S (OMX: GEN) har i dag offentliggjort, at selskabets CEO Jan van de Winkel, ph.d., vil give en præsentation om Genmab på Jefferies Autumn 2015 Global Healthcare konference i London kl. 14.40 lokal tid (kl. 15.40 dansk tid) den 18. november 2015. En webcast af præsentation vil være tilgængelig via følgende link på Genmabs hjemmeside:
-
Sukker fortjener en falske rødvin for de gode spørgsmål
-
Den her er vigtig:
-
as we flagged up at our Q3 investor call we intend to further accelerate candidates from our broad innovative pre clincial pipeline in parallel rather than sequentially in the coming years.
-
Sorry til Lithiumjay. Dit gode spørgsmål forsvandt i teknikken da vi postede det. På den konto kan der desværre være røget en eller to mere.
-
Ellers tak for mange super gode spørgsmål.
' -
Smid meget gerne spørgsmål til Zealand Pharma. Dem har vi Q&A med på fredag kl. 11.
-
Hele sessionen er her i pdf form: http://www.proinvestor.com/debat/73601
-
Han skal vel svare sådan.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind